196 related articles for article (PubMed ID: 32067746)
21. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
Sugiyama T; Mizuno M; Aoki Y; Sakurai M; Nishikawa T; Ueda E; Tajima K; Takeshima N
Jpn J Clin Oncol; 2017 Jan; 47(1):39-46. PubMed ID: 27803033
[TBL] [Abstract][Full Text] [Related]
22. Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer.
Hisamatsu T; Mabuchi S; Yoshino K; Fujita M; Enomoto T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2012 May; 22(4):623-9. PubMed ID: 22343974
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
Chu G; Liu X; Yu W; Chen M; Dong L
BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
[TBL] [Abstract][Full Text] [Related]
27. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
Mountzios G; Dimopoulos MA; Bamias A; Vourli G; Kalofonos H; Aravantinos G; Fountzilas G; Papadimitriou CA
Ann Oncol; 2009 Aug; 20(8):1362-8. PubMed ID: 19457937
[TBL] [Abstract][Full Text] [Related]
28. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
29. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
Moore KN; Herzog TJ; Lewin S; Giuntoli RL; Armstrong DK; Rocconi RP; Spannuth WA; Gold MA
Gynecol Oncol; 2007 May; 105(2):299-303. PubMed ID: 17303230
[TBL] [Abstract][Full Text] [Related]
30. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Tewari KS; Sill MW; Birrer MJ; Penson RT; Huang H; Moore DH; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
Gynecol Oncol; 2023 Apr; 171():141-150. PubMed ID: 36898292
[TBL] [Abstract][Full Text] [Related]
31. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.
Mabuchi S; Morishige K; Fujita M; Tsutsui T; Sakata M; Enomoto T; Kimura T
Gynecol Oncol; 2009 May; 113(2):200-4. PubMed ID: 19268342
[TBL] [Abstract][Full Text] [Related]
32. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.
Lissoni AA; Colombo N; Pellegrino A; Parma G; Zola P; Katsaros D; Chiari S; Buda A; Landoni F; Peiretti M; Dell'anna T; Fruscio R; Signorelli M; Grassi R; Floriani I; Fossati R; Torri V; Rulli E
Ann Oncol; 2009 Apr; 20(4):660-5. PubMed ID: 19181826
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study.
Buda A; Fossati R; Colombo N; Fei F; Floriani I; Gueli Alletti D; Katsaros D; Landoni F; Lissoni A; Malzoni C; Sartori E; Scollo P; Torri V; Zola P; Mangioni C
J Clin Oncol; 2005 Jun; 23(18):4137-45. PubMed ID: 15961761
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study.
He X; Liu J; Xiao L; Zhao M; Su T; Liu T; Han G; Wang Y
BMC Cancer; 2020 May; 20(1):381. PubMed ID: 32370739
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
36. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.
Wu Y; Jiang P; Chen Z; Li W; Dong B; Zhang Y
BMC Cancer; 2024 May; 24(1):589. PubMed ID: 38745137
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma.
Scandurra G; Scibilia G; Banna GL; D'Agate G; Lipari H; Gieri S; Scollo P
J Gynecol Oncol; 2015 Apr; 26(2):118-24. PubMed ID: 25686397
[TBL] [Abstract][Full Text] [Related]
39. Oncologic Outcomes of Stage IVB or Persistent or Recurrent Cervical Carcinoma Patients Treated With Chemotherapy at Siriraj Hospital: Thailand's Largest Tertiary Referral Center.
Ruengkhachorn I; Leelaphatanadit C; Therasakvichya S; Hunnangkul S
Int J Gynecol Cancer; 2016 Jul; 26(6):1154-61. PubMed ID: 27051060
[TBL] [Abstract][Full Text] [Related]
40. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]